摘要:目的: 觀察瑞格列奈、阿卡波糖聯合治療老年性2型糖尿病患者的臨床療效及安全性。 方法 :觀察58例2型糖尿病患者服用瑞格列奈及阿卡波糖,療程12周,監測治療前后空腹及餐后2 h血糖(FBG、PBG)、糖化血紅蛋白(HbAlc)、肝功、腎功。 結果 :FBG、PBG及HbAlc較治療前顯著下降(Plt;005),尤其是餐后血糖更為明顯(Plt;001)。無一例肝腎功能損害,也無嚴重低血糖及其它嚴重不良反應發生。 結論 :瑞格列奈聯合阿卡波糖治療2型糖尿病降糖作用確切,而且安全性、耐受性良好。Abstract: Objective: To observe the clinical efficacy and safety of combined treatment of repaglinide and acarbose in aged patients with diabetes type 2 Methods : After oral administration of repaglinide and acarbose for 12 weeks, 58 patients with type 2 diabetes were observed. The concentrations of fasting blood glucose (FBG), 2 h postprandial blood glucose (PBG), glycosylated hemoglobin (HbAlc), liver and kidney functions were monitored before and after treatment. Results : The levels of FBG, PBG and HbAlc were significantly decreased compared with pretreatment (Plt;005), especially PBG (Plt;001). No case of liver and kidney dysfunction was found, without serious hypoglycemia and other serious adverse events as well. Conclusion : Repaglinide and acarbose have the precise function in the treatment of type 2 diabetes, with good security and good tolerance.
Objective To demonstrate the efficacy, tolerability, and safety of domestic Acarbose tablet compared with Glucobay (Acarbose tablet produced by Bayer company) in patients with type 2 diabetic patients. Method A multicenter randomized controlled parallel-group comparison study was conducted. 177 Chinese type 2 diabetic patients were recruited from 4 clinical centers. The patients were divided randomly into domestic Acarbose tablet (A group) or Glucoby (B group) treatment group. The trial consisted of a 2-4 weeks equilibrated period followed by an 8 week course of treatment. Results 165 patients have finished the trial (81 in A group and 84 in B group). After 4 weeks of treatment, the mean of fasting blood glucose (FBG) in A and B group were reduced 1.61 and 2.08 mmol/L respectively, and mean of postprandial blood glucose (PBG) lowered 5.06 and 5.09mmol/L respectively. After 8 weeks of treatment, the mean of FBG were reduced 1.95 and 2.62mmol/L respectively, and mean of PBG lowered 4.88 and 5.98 mmol/L, respectively, and mean of HbA1c were lowered 1.13% and 1.20% respectively in A and B group. The differences in reduction of FBG, PBG, and HbA1c between A and B group were no statistic significance. The serum triglyceride levels and BMI were decreased significantly in both A, B groups. 3 patients who drinking wine during trial on A group had asymptomatic elevations in serum transaminases that normalized in 2 weeks after stopped drinking and Acarbose withdrawal. Flatulence was the most common side effect. Conclusions In this multicenter study, domestic Acarbose tablet 50 mg t.i.d. was an effective, safe, and generally well-tolerated therapy as similar as Glucobay in type 2 diabetic patients.
目的:觀察甘精胰島素、阿卡波糖與鹽酸貝那普利聯合治療2型糖尿病早期腎病的臨床療效。方法:將62例2型糖尿病合并糖尿病腎病III期患者用甘精胰島素作為基礎量使空腹血糖達標,三餐時聯合阿卡波糖口服控制餐后血糖,輔以鹽酸貝那普利治療,觀察治療前后血糖、血壓及尿白蛋白/肌酐的變化。結果:經甘精胰島素、阿卡波糖治療后空腹和餐后2 h血糖明顯下降,聯合鹽酸貝那普利治療可改善胰島素抵抗,并使UAER明顯下降。結論:甘精胰島素作為基礎量、聯合阿卡波糖控制血糖,輔以鹽酸貝那普利口服是治療2型糖尿病合并早期糖尿病腎病的方法之一,療效肯定,無低血糖發生。
【摘要】 目的 觀察單用二甲雙胍與二甲雙胍聯合阿卡波糖對2型糖尿病（type 2 diabetes mellitus，T2DM）降糖作用的臨床療效。 方法 對2010年1—10月就診有典型易饑多食的T2DM患者45例，隨機分為二甲雙胍組20例和二甲雙胍聯合阿卡波糖25例，療程12周。 結果 二甲雙胍組與二甲雙胍聯合阿卡波糖組治療后對患者的饑餓感和食量改善差異有統計學意義（Plt;0.05），空腹及餐后血糖差異（Plt;0.01）、空腹血糖達標比例差異（Plt;0.01）、餐后血糖達標比例差異（Plt;0.05）均有統計學意義。 結論 二甲雙胍聯合阿卡波糖能顯著改善T2DM患者的食欲及食量，從而明顯降低空腹及餐后血糖。【Abstract】 Objective To observe and compare the clinical affects and curative effects between using metformin and metformin plus acarbose in the treatment of type 2 diabetes mellitus (T2DM). Methods From January to October 2010, 45 T2DM patients with common symptoms of easy-starving and overeating were randomized into two groups and treated for 12 weeks with either metformin (n=20) or metformin plus acarbose (n=25). Results After the treatment, significant differences were found between the two groups in the improvement on patients’ sense of starving and quantity of eating (Plt;0.05), fasting and postprandial blood glucose (Plt;0.01), up-to-standard rate of fasting blood glucose (Plt;0.01), and up-to-standard rate of postprandial blood glucose (Plt;0.05). Conclusion The combination of metformin and acarbose can substantially improve the appetite and quantity of eating for patients with T2DM, hence significant reductions of fasting and postprandial blood glucose level can be feasibly achieved.